DMK PHARMACEUTICALS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.03 USD | -3.23% |
|
-40.00% | -95.72% |
| May. 08 | Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation | CI |
| Apr. 11 | North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge | DJ |
Presentation Operator MessageOperator (Operator)Good day and welcome to the Adamis Pharmaceuti...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Companyâs commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Companyâs lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Companyâs other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinsonâs disease.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -95.72% | 303K | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- DMKPQ Stock
- News DMK Pharmaceuticals Corporation
- Transcript : Adamis Pharmaceuticals Corporation, Q3 2019 Earnings Call, Nov 12, 2019